Novavax Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.441
- Today's High:
- $8.33
- Open Price:
- $7.86
- 52W Low:
- $5.605
- 52W High:
- $33.37
- Prev. Close:
- $7.82
- Volume:
- 11881559
Company Statistics
- Market Cap.:
- $788.56 million
- Book Value:
- -8.001
- Revenue TTM:
- $1.60 billion
- Operating Margin TTM:
- -38.42%
- Gross Profit TTM:
- $-156045000
- Profit Margin:
- -36.73%
- Return on Assets TTM:
- -17.81%
- Return on Equity TTM:
- -898.2%
Company Profile
Novavax Inc had its IPO on 1995-12-05 under the ticker symbol NVAX.
The company operates in the Healthcare sector and Biotechnology industry. Novavax Inc has a staff strength of 1,992 employees.
Stock update
Shares of Novavax Inc opened at $7.86 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.44 - $8.33, and closed at $7.91.
This is a +1.15% increase from the previous day's closing price.
A total volume of 11,881,559 shares were traded at the close of the day’s session.
In the last one week, shares of Novavax Inc have slipped by -3.65%.
Novavax Inc's Key Ratios
Novavax Inc has a market cap of $788.56 million, indicating a price to book ratio of 49.522 and a price to sales ratio of 0.4812.
In the last 12-months Novavax Inc’s revenue was $1.60 billion with a gross profit of $-156045000 and an EBITDA of $-579000000. The EBITDA ratio measures Novavax Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Novavax Inc’s operating margin was -38.42% while its return on assets stood at -17.81% with a return of equity of -898.2%.
In Q2, Novavax Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 128.3%.
Novavax Inc’s PE and PEG Ratio
- Forward PE
- 0.5781
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-7 per share while it has a forward price to earnings multiple of 0.5781 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novavax Inc’s profitability.
Novavax Inc stock is trading at a EV to sales ratio of 0.2137 and a EV to EBITDA ratio of -0.4072. Its price to sales ratio in the trailing 12-months stood at 0.4812.
Novavax Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.69 billion
- Total Liabilities
- $1.60 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $7.78 million
- Dividend Payout Ratio
- 0%
Novavax Inc ended 2024 with $1.69 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.69 billion while shareholder equity stood at $-754519000.00.
Novavax Inc ended 2024 with $0 in deferred long-term liabilities, $1.60 billion in other current liabilities, 952000.00 in common stock, $-4511786000.00 in retained earnings and $128.37 million in goodwill. Its cash balance stood at $505.91 million and cash and short-term investments were $505.91 million. The company’s total short-term debt was $953,000 while long-term debt stood at $167.25 million.
Novavax Inc’s total current assets stands at $1.13 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $394.89 million compared to accounts payable of $87.25 million and inventory worth $23.49 million.
In 2024, Novavax Inc's operating cash flow was $0 while its capital expenditure stood at $7.78 million.
Comparatively, Novavax Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.91
- 52-Week High
- $33.37
- 52-Week Low
- $5.605
- Analyst Target Price
- $21.4
Novavax Inc stock is currently trading at $7.91 per share. It touched a 52-week high of $33.37 and a 52-week low of $33.37. Analysts tracking the stock have a 12-month average target price of $21.4.
Its 50-day moving average was $8.16 and 200-day moving average was $9.15 The short ratio stood at 5.94 indicating a short percent outstanding of 0%.
Around 59.7% of the company’s stock are held by insiders while 7060.6% are held by institutions.
Frequently Asked Questions About Novavax Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.